Pfizer Aktie News

Pfizer reported another quarter of stagnation, with Q3 2025 revenue and EPS both declining year-over-year despite beating consensus estimates. PFE's revenue mix remains weak, with Primary Care sales dropping 15.6% and only Oncology showing growth ahead of inflation; management guidance remains largely unchanged. The forward P/E ratio is expected to stagnate, and low valuation multiples reflect ...

Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.

Pfizer beat third-quarter expectations Tuesday, though both sales and profit fell year over year. The company also hiked its profit view.

Shares of Pfizer ( NYSE: PFE ) lost 9.90% over the past month after gaining 10.02% the month prior.

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continue to decline.

Pfizer reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit outlook as it cuts costs, even as sales for the period fell. The results come weeks after Pfizer became the first drugmaker to strike a deal with President Donald Trump to voluntarily sell its medications for less.

Pfizer lifted its full-year profit forecast for the second time in a row on Tuesday, buoyed by strong demand for its blockbuster heart treatment and blood thinner.

NEW YORK--(BUSINESS WIRE)--Pfizer Q3-25 Earnings Release.